General Information of Drug Combination (ID: DCKY9IF)

Drug Combination Name
Salbutamol Roflumilast
Indication
Disease Entry Status REF
COPD Phase 1 [1]
Component Drugs Salbutamol   DMN9CWF Roflumilast   DMPGHY8
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Salbutamol
Disease Entry ICD 11 Status REF
Acute asthma CA23 Approved [2]
Adult respiratory distress syndrome CB00 Approved [3]
Severe asthma CA23 Approved [4]
Salbutamol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Agonist [7]
------------------------------------------------------------------------------------
Salbutamol Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Salbutamol Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [9]
Carboxylesterase 1 (CES1) DEB30C5 EST1_HUMAN Metabolism [10]
Sulfotransferase 1A3 (SULT1A3) DEP7E8X ST1A3_HUMAN Metabolism [11]
------------------------------------------------------------------------------------
Salbutamol Interacts with 7 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Decreases Response To Substance [12]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Increases Expression [13]
Renin (REN) OT52GZR2 RENI_HUMAN Increases Expression [14]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Decreases Expression [15]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [16]
Creatine kinase M-type (CKM) OTME0KO7 KCRM_HUMAN Increases Secretion [17]
PTB-containing, cubilin and LRP1-interacting protein (PID1) OT5YJ7FI PCLI1_HUMAN Increases Expression [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DOT(s)
Indication(s) of Roflumilast
Disease Entry ICD 11 Status REF
Asthma CA23 Approved [5]
Type-2 diabetes 5A11 Phase 1 [6]
Chronic obstructive pulmonary disease CA22 Withdrawn from market [5]
Atopic dermatitis EA80 Discontinued in Phase 2 [5]
Roflumilast Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Phosphodiesterase 4 (PDE4) TTV5CGO NOUNIPROTAC Modulator [18]
------------------------------------------------------------------------------------
Roflumilast Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [19]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [19]
------------------------------------------------------------------------------------
Roflumilast Interacts with 8 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B (PDE8B) OT4217NK PDE8B_HUMAN Decreases Activity [20]
3',5'-cyclic-AMP phosphodiesterase 4A (PDE4A) OTMUUZLF PDE4A_HUMAN Decreases Activity [20]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [21]
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B) OTOA8WU2 PDE4B_HUMAN Decreases Activity [20]
3',5'-cyclic-AMP phosphodiesterase 4C (PDE4C) OTI8VMHZ PDE4C_HUMAN Decreases Activity [20]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Decreases Activity [20]
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B (PDE3B) OT1GI1TE PDE3B_HUMAN Decreases Activity [20]
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (PDE3A) OTKUW1WT PDE3A_HUMAN Decreases Activity [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DOT(s)

References

1 ClinicalTrials.gov (NCT01313494) A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 558).
3 Effects of nebulized salbutamol on respiratory mechanics in adult respiratory distress syndrome. Intensive Care Med. 1997 Jan;23(1):58-64.
4 Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: Randomized clinical trial. Pediatr Pulmonol. 2019 Apr;54(4):372-377.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6962).
6 ClinicalTrials.gov (NCT01664624) Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes. U.S. National Institutes of Health.
7 Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
8 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
9 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
10 Effect of carboxylesterase 1 c.428G>A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol. 2015 Nov;80(5):1131-8.
11 SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? Drug Test Anal. 2015 Feb;7(2):109-13.
12 beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
13 Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis. Toxicol Sci. 2023 Nov 28;196(2):200-217. doi: 10.1093/toxsci/kfad088.
14 Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol. 1987 Nov;24(5):645-53. doi: 10.1111/j.1365-2125.1987.tb03224.x.
15 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
16 Levalbuterol inhibits human airway smooth muscle cell proliferation: therapeutic implications in the management of asthma. Int Arch Allergy Immunol. 2006;139(3):225-36. doi: 10.1159/000091168. Epub 2006 Jan 27.
17 Elevation of creatine kinase from skeletal muscle associated with inhaled albuterol. Ann Allergy Asthma Immunol. 1996 Dec;77(6):488-90. doi: 10.1016/S1081-1206(10)63356-X.
18 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
19 Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol. 2011 Apr;51(4):586-93.
20 Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J Pharmacol Exp Ther. 2005 Aug;314(2):846-54. doi: 10.1124/jpet.105.083519. Epub 2005 May 18.
21 Roflumilast protects from cisplatin-induced testicular toxicity in male rats and enhances its cytotoxicity in prostate cancer cell line. Role of NF-B-p65, cAMP/PKA and Nrf2/HO-1, NQO1 signaling. Food Chem Toxicol. 2021 May;151:112133. doi: 10.1016/j.fct.2021.112133. Epub 2021 Mar 20.